Formula I Compound Mitigates Chemotherapy-Induced Anemia

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a significant unmet need for medicaments that can improve survival rates and slow tumor progression in cancer patients, particularly for those with lung cancer or adenocarcinoma, while also maintaining normal bodily functions and preventing chemotherapy-induced anemia.

Innovation Solution

The use of a Formula (I) compound, specifically 2,2'-dithio-bis-ethane sulfonate or its pharmaceutically acceptable salts, in combination with taxane and platinum medicaments, such as paclitaxel and cisplatin, to enhance chemotherapy efficacy, prevent anemia, and maintain hematological and erythropoietin functions in cancer patients.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemotherapeutic agents are used to treat cancer, then tumor progression is slowed and survival time is increased, but chemotherapy-induced anemia occurs and hematological function deteriorates

Engineering Contradiction:

Improvecancer treatment efficacyVSAvoidchemotherapy-induced anemia

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a Formula (I) compound as an intermediary substance that mediates between the chemotherapeutic agent and the patient's hematological system. This compound protects hematopoietic stem cells from chemotherapy-induced damage while allowing the chemotherapeutic agent to maintain its anti-tumor efficacy, thus resolving the contradiction between cancer treatment effectiveness and prevention of chemotherapy-induced anemia

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The Formula (I) compound is administered to patients before or during chemotherapy treatment to preemptively protect against anemia. By establishing protective mechanisms in advance through erythropoietin stimulation and hematopoietic support, the compound prevents the harmful effects of chemotherapy on blood cell production while maintaining the desired anti-cancer effects

Inventive Principle:

Principle #9Preliminary anti-action

2Reliability

If chemotherapeutic agents are used to treat cancer, then tumor progression is slowed, but normal bodily functions and quality of life deteriorate

Engineering Contradiction:

Improvecancer treatment efficacyVSAvoidquality of life

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The Formula (I) compound converts the harmful side effects of chemotherapy into beneficial outcomes. By stimulating erythropoietin production and protecting hematopoietic stem cells, the compound transforms chemotherapy-induced hematological damage into improved blood cell production and enhanced quality of life, while maintaining tumor progression control

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Productivity

If higher doses of chemotherapeutic agents are used, then tumor progression is more effectively slowed, but anemia and side effects worsen

Engineering Contradiction:

Improvetumor progression controlVSAvoidanemia and side effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the therapeutic parameter by introducing a new compound (Formula (I)) that modifies the relationship between chemotherapeutic dose and side effect severity. This compound enables dose intensification by protecting against anemia, allowing higher chemotherapeutic doses to be administered safely while maintaining or improving tumor progression control without proportionally increasing harmful effects

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP2249825B1Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions

Publication Date: 2015.10.07 BIONUMERIK PHARMACEUTICALS INC

Figure 1
Figure 2
Figure 3

AI summary

The present invention discloses and claims: (i) compositions, methods, and kits which lead to an increase in patient survival time in cancer patients receiving chemotherapy; (ii) compositions and methods which cause cytotoxic or apoptotic potentiation of the anti-cancer activity of chemotherapeutic agents; (iii) compositions and methods for maintaining or stimulating hematological function in patients in need thereof, including those patients suffering from cancer; (iv) compositions and methods for maintaining or stimulating erythropoietin function or synthesis in patients in need thereof, including those patients suffering from cancer; (v) compositions and methods for mitigating or preventing anemia in patients in need thereof, including those patients suffering from cancer; (vi) compositions and methods for maintaining or stimulating pluripotent, multipotent, and unipotent normal stem cell function or synthesis in patients in need thereof, including those patients suffering from cancer; (vii) compositions and methods which promote the arrest or retardation of tumor progression in those cancer patients receiving chemotherapy; (viii) compositions and methods for increasing patient survival and/or delaying tumor progression while maintaining or improving the quality of life in a cancer patient receiving chemotherapy; (ix) novel methods of the administration of taxane and/or platinum medicaments and a Formula (I) compound of the present invention to a cancer patient; and (x) kits to achieve one or more of the aforementioned physiological effects in a patient in need thereof, including those patients suffering from cancer.